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Brain-Derived Neurotrophic Factor (BDNF) 
 
Enhances integration of regenerated axons 
by promoting synapse formation or maybe 
an increase in the efficiency of signal 
transduction of the regenerated axons.  
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Spinal Cord Injury 
Primary damage 
 
•A hit breaks the vertebrae 
•Bone fragments tear spinal cord tissue 
Secondary wave of damage 
 
•Changes in blood flux 
•Leakage of neurotransmitters (glutamate) and free radicals 
•Invasion of immune cells 
Increase in cytokine concentration 
Fight against infection and clean waste 
Scar formation 
 
• Accumulation of astrocytes 
• Pericytes  
•Secretion of chondroitin sulphate proteoglycans (CSPG) 
Therapeutic Genes 




• Transgene insert capacity: 4.5kb 
• Serotypes:  
AAV2  neurons 
AAV5  glial cells (few neurons)  
AAV1  glial cells (few neurons) 
AAV9  good motor neuron transfection 
 
• scAAV  Double-stranded AAVs (self 
complementary AAV) more effective in 





• Transgene insert capacity: 6kb 
•Good at targeting astroglia 
•Risk of insertional mutagenesis 
•Commonly pseudotyped with:  
 VSV-G to target spinal cord glial cells 
 Rabies-G virus to target  distant spinal 
motor neurons by retrograde transport 
when injected intramuscularly. 








•Transgene insert capacity: 8-30kb 
•They generate immune response.  









• Transgene insert capacity: 30-40kb 
•High  capacity of in vivo transgene expression 





•Low efficienct gene delivery and expression  
Glial cell-line Derived Neurotrophic Factor 
(GDNF) 
 
Exerts tropic effects on adult spinal axons 
and Schwann cells that contribute to axon 
growth after injury.  
Neurotrophin-3 (NT-3) 
 
Induces growth of corticospinal axons.  
 
Transforming Growth Factor-α (TFG-α) 
 
Transforms astrocytes to a growth 
supportive phenotype after SCI.  
 
 
Gene therapy offers a hopeful strategy to treat spinal cord injury. Previously, systemic administration of Neurotrophic factors used to produce secondary effects and toxicity, since high doses were 
required to get to the CNS. Later, cell transplants showed a promising potential, although engraftment and survival of transplanted cells is not 100% efficient. Hence, gene therapy offers a way to 
locally administer a therapeutic gene at a clinical doses so that the minimum toxicity is caused.  
However, viral vectors carry some risk associated. More efficient and less dangerous vehicles are required to pass from pre-clinical to clinical trials. A future approach would be combinational 
strategies, where genetically engineered cells could be obtained by ex vivo gene transfer and lately transplanted into the spinal cord. Biomaterials to serve as bridges between both parts of the glial 
scar are also being tested. Moreover, strategies where promoters could be induced to express or not the therapeutic gene would be of great clinical interest, and are already being tested. 
To sum up, there is no one and only strategy that will cure SCI in short term, although great efforts are directed to find the combination that will be both efficient and safe enough for being tested in 
patients.  
 
Conclusions and Discussion 
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